Slc40A1 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Solute Carrier Family 40 Member 1 (Ferroportin) [1]
| Gene Symbol | SLC40A1 |
|---|---|
| Full Name | Solute Carrier Family 40 Member 1 (Ferroportin) |
| Chromosomal Location | 2q32.2 |
| NCBI Gene ID | 30061 |
| OMIM | 604653 |
| Ensembl ID | ENSG00000138448 |
| UniProt ID | Q9NP59 |
| Associated Diseases | Neurodegeneration with Brain Iron Accumulation (NBIA), Type IV (Ferroportin Disease), Alzheimer's Disease, Parkinson's Disease |
SLC40A1 Gene is involved in biological pathways relevant to neurodegenerative diseases. It plays important roles in neuronal function, cellular signaling, or stress response mechanisms.
Dysregulation or mutations in this gene/protein contribute to the pathogenesis of Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders.
SLC40A1 encodes ferroportin, the only known iron exporter in mammals. This protein is essential for iron homeostasis and is expressed in cells that export iron, including macrophages, hepatocytes, and enterocytes.
Key functions include:
Ferroportin is a multipass transmembrane protein with 12 transmembrane domains. It exports Fe2+ iron, which is then oxidized to Fe3+ by hephaestin for transferrin binding.
SLC40A1 mutations cause a form of NBIA:
Mutations can be gain-of-function (leading to iron retention) or loss-of-function (causing iron overload syndrome similar to hemochromatosis).
Heterozygous SLC40A1 mutations cause ferroportin disease:
Ferroportin dysfunction may contribute to AD:
Iron metabolism is altered in PD:
SLC40A1 shows cell-type specific expression [2]:
Expression is regulated by iron levels and hepcidin (which causes ferroportin internalization and degradation).
Ferroportin is a unique iron exporter with distinct structural features [3]:
Protein architecture:
Iron export process:
Regulation by hepcidin [4]:
Ferroportin is central to cellular iron balance:
| Cell Type | Role | Regulation |
|---|---|---|
| Enterocytes | Dietary iron absorption | Ferroxidase activity |
| Hepatocytes | Plasma iron supply | Iron stores |
| Macrophages | Iron recycling | Erythropoietic demand |
| Neurons | Brain iron supply | Local regulation |
| Microglia | Immune cell iron | Inflammatory signals |
The brain has specialized iron handling mechanisms [5] [6]:
Blood-brain barrier iron transport:
Neuronal iron import:
Glial iron handling:
Brain-specific ferroportin expression [2:1] [7]:
SLC40A1 mutations cause a distinctive form of NBIA [1:1] [8]:
Pathogenesis:
Clinical Presentation:
Genotype-phenotype correlations:
| Mutation Type | Phenotype | Iron Pattern |
|---|---|---|
| Gain-of-function | NBIA Type IV | Brain iron accumulation |
| Loss-of-function | Ferroportin disease | Systemic iron overload |
Hereditary ferroportin disease caused by SLC40A1 mutations [9]:
Type A (loss-of-function):
Type B (gain-of-function):
Ferroportin dysfunction contributes to AD pathogenesis [10]:
Brain iron dysregulation:
Ferroptosis mechanism:
Amyloid interaction:
Therapeutic implications:
Iron metabolism alterations in PD [11]:
Substantia nigra iron:
Ferroportin expression:
Dopaminergic neuron vulnerability:
Therapeutic targets:
Ferroportin plays a role in neuroimmune interactions [7:1]:
Microglial iron handling:
Inflammatory signaling:
Iron and neuroinflammation:
Multiple therapeutic strategies are being developed:
| Approach | Status | Mechanism |
|---|---|---|
| Hepcidin antagonists | Preclinical | Restore ferroportin function |
| Ferroportin agonists | Discovery | Increase iron export |
| Iron chelators | Clinical | Reduce iron burden |
| Gene therapy | Research | Deliver functional SLC40A1 |
Current chelation approaches for NBIA and related disorders:
The study of Slc40A1 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Last updated: 2026-03-05
Matsuura K, et al. Ferroportin in neurons. J Neurosci Res. 2019. ↩︎ ↩︎
Drakesmith H, et al. Ferroportin and iron export. Nat Rev Gastroenterol Hepatol. 2015. ↩︎
Ganz T, et al. Hepcidin and ferroportin in iron homeostasis. Hematology Am Soc Hematol Educ Program. 2013. ↩︎
Anderson GJ, et al. Iron metabolism in the brain. Neurobiology of Aging. 2012. ↩︎
Pinero DJ, et al. Brain iron homeostasis and neurodegenerative disease. J Neural Transm. 2019. ↩︎
Dmitriev AD, et al. Ferroportin and neuroinflammation. J Neuroinflammation. 2019. ↩︎ ↩︎
Barton JC, et al. SLC40A1 mutations in iron overload. Haematologica. 2019. ↩︎
Pelizzo G, et al. Ferroportin disease and iron accumulation. Blood Cells Mol Dis. 2018. ↩︎
Chen X, et al. Iron metabolism in Alzheimer's disease. Front Aging Neurosci. 2020. ↩︎
Li K, et al. Ferroportin in Parkinson's disease. Mov Disord. 2021. ↩︎